ELND005 for Agitation and Aggression in Alzheimer s Disease (HARMONY-AD Study): Phase 2/3 design and clinical outcomes
|
|
|
- Rosamond Walters
- 6 years ago
- Views:
Transcription
1 ELND005 for Agitation and Aggression in Alzheimer s Disease (HARMONY-AD Study): Phase 2/3 design and clinical outcomes Anton P. Porsteinsson MD 1, Susan Abushakra MD 2, Merce Boada 3, Ira Goodman 4, Giovanni Marotta 5, Aleksandra Pastrak MD PhD 2, Earvin Liang PhD 2, Rachelle Doody MD PhD 6, Bruno Vellas 7, Constantine Lyketsos MD MHS 8 1 University of Rochester School of Medicine and Dentistry, Rochester, NY, USA; 2 Transition Therapeutics Ireland Limited, Dublin, Ireland; 3 Fundacion ACE, Barcelona Alzheimer Treatment & Research Center, Barcelona, Spain; 4 Compass Research, Orlando, FL, USA; 5 Centre for Memory and Aging, Gerontion Research, Toronto, Canada; 6 Department of Neurology, Baylor College of Medicine, Houston TX, USA; 7 University of Toulouse, Alzheimer s Disease Research Center, Toulouse, France; 8 Department of Psychiatry, Johns Hopkins University, Baltimore MD, USA HARMONY-AD Study was sponsored by Transition Therapeutics Inc., Toronto, Canada s1
2 DISCLOSURES Dr. Porsteinsson reports receipt of a grant to his institution from AstraZeneca, Avanir, Baxter, Biogen, BMS, Eisai, Elan, Ely Lilly, EnVivo, Genentech/Roche, Janssen Alzheimer Initiative, Medivation, Merck, Pfizer, Toyama, Transition Therapeutics, the National Institutes of Health (NIH), the National Institute of Mental Health (NIMH), the National Institute on Aging (NIA), and the Department of Defense; paid consultancy for Elan, Janssen Alzheimer Initiative, Lundbeck, Pfizer, Transition Therapeutics, and TransTech Pharma; membership on data safety and monitoring boards for Quintiles, Functional Neuromodulation, and the New York State Psychiatric Institute; participation on a speaker s bureau for Forest; and development of educational presentations for CME Inc. and PVI. Travel support was provided by Transition Therapeutics. s2
3 90% of AD patients develop neuropsychiatric symptoms (NPS) over the course of disease AGITATION/AGGRESSION IN ALZHEIMER S DISEASE Up to 60% of AD patients develop agitation/aggression 1 Greater ADL impairment 2 Worse quality of life 3 Earlier institutionalization 4 Major source of caregiver burden 5 $10,000/year additional care costs 6 Shorter time to severe dementia 7 Accelerated mortality 7 1 Cummings J, Back C. (1998); 2 Lyketsos et al. (1997); 3 Gonzales-Salvador et al. (1999); 4 Steele et al. (1990); 5 Lyketsos et al. (1999); 6 Murman et al. (2002); 7 Peters et al. (2015) s3
4 ELND005 FOR AGITATION/AGGRESSION: MECHANISM OF ACTION Cingulate Gyrus Thalamus Prefrontal cortex Nucleus accumbens Amygdala Hippocampus myo-inositol myo-inositol plays important role in the Phospho-inositol cycle and signaling of GPCR 1,2 myo-inositol is found elevated in neuropsychiatric diseases including AD ELND005 (scyllo-inositol) reduces brain myo-inositol levels by ~45% Regulation of myo-inositol may modulate neuronal signaling in response to neurotransmitters and growth factors 1 Berridge et al. Cell. 1989; 2 Schloesser et al. Neuropsychopharm s4
5 AG201: ELND005 PHASE 2 STUDY FOR THE TREATMENT OF AGITATION AND AGGRESSION IN AD N = 350 Probable AD by NIA/AA criteria Stable AD drugs and psychotropics MMSE of 5 to 24 at screening NPI Agitation/Aggression 4 Require pharmacological intervention Randomized to: Placebo ELND mg BID PRIMARY ENDPOINT Change from baseline in NPI-C combined agitation and aggression score (NPI-C A+A) Daily dosing (12 weeks) Safety extension (36 weeks) Loading 1000 mg BID 4 weeks Maintenance 250 mg BID 8 weeks s5
6 NEUROPSYCHIATRIC INVENTORY CLINICIAN RATING SCALE (NPI-C) AGITATION AND AGGRESSION DOMAINS (NPI-C A+A) Max Score = 63 (addition of 21 item scores; severity 0-3) Upset/resist activity? AGITATION (13 items) Pace nervously? AGGRESSION (8 items) Shout/curse? Common to NPI Stubborn Aggressively leaving residence? Slam/kick/throw? Common to NPI Uncooperative/resistive? Inappropriately using phone for help? Hurt/hit others? Repetitive questions? Hoard objects? Grab/push others? Restless? Hide objects? Argumentative? Fidget? Intrusive/entering another s room? Complain about health? Conflict with others? Refuse medication? Dangerous actions? De Medeiros et al s6
7 AG201 STUDY POPULATION SUMMARY PLACEBO ELND005 Randomized (Safety population) mitt population Completed Discontinued Adverse events 7 8 Withdrawal by subjects 9 7 Other 2 3 BASELINE CHARACTERISTICS (mitt POPULATION ) Gender (M/F, %) 43% / 57% 45% / 55% Race (% Caucasian) 86% 88% Age (Mean SD) Region North America 91% 91% Mild/moderate AD (MMSE 16) 49% 45% Psychotropic medication use 55% 55% Anti-depressants / Anti-psychotics 47% / 20% 47% /20% Apo E4 positive 56% 57% Baseline MMSE (mean SD) 15.0 (5.9) 14.2 (5.7) NPI-C A+A (mean SD) (max score 63) 19.1 (10.9) 18.3 (9.8) NPI agitation/aggression (mean SD) (max score 12) 7.2 (2.4) 7.3 (2.6) Total NPI (mean SD) (max score 144) 47.8 (26.6) 46.6 (24.4) s7
8 LS Mean Change from Baseline PRIMARY OUTCOME: NPI-C AGITATION + AGGRESSION NPI-C A+A Change from Baseline mitt Population (MMRM) Placebo (n=167) ELND005 (n=167) The study did not meet the primary endpoint, NPI-C A+A change from baseline at week 12 Secondary endpoints, NPI Agit/Agg and madcs-cgic, were not significant Study Week s8
9 Week 12 Change from Baseline SE LS Mean Change from Baseline SE POST-HOC ANALYSIS: NPI-C A+A CHANGE FROM BASELINE CORRELATION BETWEEN NPI-C A+A CUTOFF and WEEK 12 CHANGE FROM BASELINE BL NPI-C A+A 22 =-2.4 p=0.250 =-4.7 p=0.055 =-5.9 p=0.036 =-6.8 p=0.027 =-8.1 p=0.014 =-9.7 p=0.012 p=0.165 p=0.155 =-4.7 p=0.055 Placebo ELND Baseline NPI-C A+A Cut-off BL 53/49 W4 52/48 W8 51/48 Study Week (n=placebo/elnd005) W12 47/46 s9
10 Mean baseline score NPI-C A+A SUBITEM MEAN BASELINE SCORES (ALL SUBJECTS) Baseline NPI-C A+A Subitem Mean Score < 22 (n=232) 22 (n=102) Agitation Aggression Most prevalent agitation/aggression behaviors in patients with NPI-C < 22 include UPSET, STUBBORN, RESISTIVE, ASK, and SHOUT In more severe patients (NPI-C A+A 22), behaviors such as RESTLESS, FIDGET, PACE, REFUSE, COMPLAIN, HOARD, HIDE, SLAM, HURT, PUSH, ARGUE, INTRUSIVE, CONFLICT, and DANGER become prevalent/severe s10
11 NPI-C A+A SUBITEM CHANGE FROM BASELINE AT WEEK 12 Baseline NPI-C A+A < 22 (N=108/111) Placebo ELND005 Baseline NPI-C A+A 22 (N=47/46) s11
12 SAFETY ANALYSES s12
13 OVERVIEW OF ADVERSE EVENTS PLACEBO (N=175) ELND005 (N=175) Any TEAE 95 (54.3%) 99 (56.6%) Any study drug-related TEAE 26 (14.9%) 23 (13.1%) Serious AEs 5 (2.9%) 17 (9.7%) Serious study drug-related AEs 0 (0.0%) 2 (1.1%) Death 0 (0.0%) 0 (0.0%) SUBJECTS WITHDRAWN DUE TO AN ADVERSE EVENTS TEAE 7 (4.0%) 8 (4.6%) Drug-related TEAE 3 (1.7%) 5 (2.9%) SUBJECTS WITH TEAES BY MAXIMUM SEVERITY Mild 37 (21.1%) 36 (20.6%) Moderate 50 (28.6%) 48 (27.4%) Severe 7 (4.0%) 15 (8.6%) Life-threatening 1 (0.6%) 0 (0.0%) s13
14 SUMMARY OF TEAES INCIDENCE 2% ELND005 GROUP PREFERRED TERM PLACEBO (N=175) ELND005 (N=175) Agitation 13 (7.4%) 14 (8.0%) Diarrhea 5 (2.9%) 14 (8.0%) Urinary tract infection 7 (4.0%) 12 (6.9%) Fall 9 (5.1%) 11 (6.3%) Cough 2 (1.1%) 7 (4.0%) Lethargy 2 (1.1%) 6 (3.4%) Insomnia 7 (4.0%) 5 (2.9%) Vomiting 5 (2.9%) 5 (2.9%) Constipation 2 (1.1%) 4 (2.3%) Gait disturbance 1 (0.6%) 4 (2.3%) Headache 2 (1.1%) 4 (2.3%) s14
15 HARMONY AD STUDY CONCLUSION PRIMARY ANALYSIS ELND005 did not meet the primary efficacy endpoint (NPI-C A+A) ELND005 showed an acceptable safety profile POST HOC ANALYSIS ELND005 showed significant improvement in patients with more severe agitation and aggression Most prevalent agitation/aggression behaviors in patients with baseline NPI-C < 22 include UPSET, STUBBORN, RESISTIVE, ASK, and SHOUT In more severe patients (NPI-C A+A 22), behaviors such as RESTLESS, FIDGET, PACE, REFUSE, COMPLAIN, HOARD, HIDE, SLAM, HURT, PUSH, ARGUE, INTRUSIVE, CONFLICT, and DANGER become more prevalent ELND005 resulted in numerical benefits in 20 out of 21 A/A symptoms in severe A+A patients s15
16 Our sincere thanks to HARMONY AD clinical sites and to their AD patients/caregivers for their contributions s16
Mild Behavioral Impairment (MBI): Symptoms, Prodrome, or False Alarm?
Mild Behavioral Impairment (MBI): Symptoms, Prodrome, or False Alarm? Constantine G. Lyketsos, MD, MHS Chair of Psychiatry, Johns Hopkins Bayview Elizabeth Plank Althouse Professor, Johns Hopkins University
Mild Cognitive Impairment Symposium January 19 and 20, 2013
Highlights of Biomarker and Clinical Outcomes in Recent AD Treatment Trials Stephen Salloway, MD, MS Professor of Neurology and Psychiatry Alpert Medical School, Brown University Mild Cognitive Impairment
Disclosure. Speaker Bureaus. Grant Support. Pfizer Forest Norvartis. Pan American Health Organization/WHO NIA HRSA
Disclosure Speaker Bureaus Pfizer Forest Norvartis Grant Support Pan American Health Organization/WHO NIA HRSA How Common is Psychosis in Alzheimer s Disease? Review of 55 studies 41% of those with Alzheimer
11/11/2016. Relevant Disclosures Current or past. Outline
Management of Agitation in Dementia 2016 Update Constantine G. Lyketsos, MD, MHS Interim Chair of Psychiatry, Johns Hopkins Medicine Elizabeth Plank Althouse Professor, Johns Hopkins University kostas@jhmi.edu
EXPEDITION3: A Phase 3 Trial of Solanezumab in Mild Dementia due to Alzheimer s Disease
EXPEDITION3: A Phase 3 Trial of in Mild Dementia due to Alzheimer s Disease Lawrence S. Honig, MD, PhD On behalf of the EXPEDITION3 Study Team Disclosure Statement I will discuss investigational use only.
Management of the Acutely Agitated Long Term Care Patient
Management of the Acutely Agitated Long Term Care Patient 80 60 Graying of the Population US Population Over Age 65 Millions of Persons 40 20 0 1900 1920 1940 1960 1980 1990 2010 2030 Year Defining Dementia
Assessing and Treating Agitation Associated with Alzheimer s Disease
AXS-05 R&D Day April 24, 2018 Assessing and Treating Agitation Associated with Alzheimer s Disease Marc E. Agronin, MD VP, Behavioral Health and Clinical Research, Miami Jewish Health Affiliate Associate
Responsiveness of the QUALID to Improved Neuropsychiatric Symptoms in Patients with Alzheimer s Disease
ORIGINAL RESEARCH Responsiveness of the QUALID to Improved Neuropsychiatric Symptoms in Patients with Alzheimer s Disease Hadas Benhabib 1, Krista L. Lanctôt, PhD 1,2,4, Goran M. Eryavec, MD, FRCPC 3,4,
Effect of Citalopram on Agitation in Alzheimer Disease The CitAD Randomized Clinical Trial
Research Original Investigation Effect of Citalopram on Agitation in Alzheimer Disease The CitAD Randomized Clinical Trial Anton P. Porsteinsson, MD; Lea T. Drye, PhD; Bruce G. Pollock, MD, PhD; D. P.
Clinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease
Clinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease Professor Clive Ballard Dr Byron Creese University of Exeter, UK Guardian guide for 2018: Top
Neuropsychiatric Syndromes
Neuropsychiatric Syndromes Susan Czapiewski,MD VAHCS December 10, 2015 Dr. Czapiewski has indicated no potential conflict of interest to this presentation. She does intend to discuss the off-label use
11/11/2016. Disclosures. Natural history of BPSD. Objectives. Assessment of BPSD. Behavioral Management of Persons with Alzheimer s Disease
Disclosures Behavioral Management of Persons with Alzheimer s Disease Wisconsin Association of Medical Directors November 17, 2016 Art Walaszek, M.D. Professor of Psychiatry UW School of Medicine & Public
Aging Really Matters New Directions in Understanding Late Life Neuropsychiatric Disorders
Aging Really Matters New Directions in Understanding Late Life Neuropsychiatric Disorders Constantine G. Lyketsos, MD, MHS Chair of Psychiatry, Johns Hopkins Bayview Elizabeth Plank Althouse Professor,
42-Lowering Agent, in Alzheimer s s Disease: A Phase 2 Trial of up to 24 Months of Treatment. Gordon K. Wilcock*, University of Oxford, UK
Efficacy and Safety of Tarenflurbil (Flurizan ), a Selective Aβ42A 42-Lowering Agent, in Alzheimer s s Disease: A Phase 2 Trial of up to 24 Months of Treatment Gordon K. Wilcock*, University of Oxford,
RESEARCH AND PRACTICE IN ALZHEIMER S DISEASE VOL 10 EADC OVERVIEW B. VELLAS & E. REYNISH
EADC BRUNO VELLAS 14/01/05 10:14 Page 1 EADC OVERVIEW B. VELLAS & E. REYNISH (Toulouse, France, EU) Bruno Vellas: The European Alzheimer's Disease Consortium is a European funded network of centres of
SYNOPSIS. Trial No.: RIS-USA-70 Clinical phase: III. JRF, Clinical Research Report RIS-USA-70, 16 October, 1998 N Trial period: Start: 20 Nov 95
SYNOPSIS Trial identification and protocol summary Company: Janssen Research Foundation Finished product: RISPERDAL Active ingredient: Risperidone (R064,766) Title: An open-label, long-term study of risperidone
A 24-Week, Open-Label Extension Study to Investigate the Long-Term Safety,
1 A 24-Week, Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of 13.3 mg/24 h Rivastigmine Patch in Patients with Severe Alzheimer s Disease Martin R. Farlow,
FROM THE ALZHEIMER S ASSOCIATION INTERNATIONAL CONFERENCE 2018 NEW RESEARCH FOCUSES ON TREATING NON-COGNITIVE SYMPTOMS OF PEOPLE WITH DEMENTIA
CONTACT: Alzheimer s Association AAIC Press Office, 312-949-8710, aaicmedia@alz.org Niles Frantz, Alzheimer s Association, 312-335-5777, niles.frantz@alz.org FROM THE ALZHEIMER S ASSOCIATION INTERNATIONAL
SYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-USA-232 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-USA-232 Title of Study: Efficacy and Safety of a Flexible Dose of Risperidone Versus Placebo in the Treatment of Psychosis of Alzheimer's Disease Principal Investigator: M.D.
Pharmacological Treatments for Neuropsychiatric Symptoms in Dementia 3/22/2018
Pharmacological Treatments for Neuropsychiatric Symptoms in Dementia 3/22/2018 Mary Ellen Quiceno, MD, FAAN Associate Professor of Neurology UNTHSC Center for Geriatrics 855 Montgomery Street, PCC 4, Ft.
Optimal Management of Challenging Behaviours in Dementia: An Update on Pharmacologic and Non-Pharmacologic Approaches
Optimal Management of Challenging Behaviours in Dementia: An Update on Pharmacologic and Non-Pharmacologic Approaches Andrea Iaboni, MD, DPhil, FRCPC Toronto Rehab Institute, UHN Learning objectives Recognize
Screening and Management of Behavioral and Psychiatric Symptoms Associated with Dementia
Screening and Management of Behavioral and Psychiatric Symptoms Associated with Dementia Measure Description Percentage of patients with dementia for whom there was a documented screening* for behavioral
NEUROPSYCHOMETRIC TESTS
NEUROPSYCHOMETRIC TESTS CAMCOG It is the Cognitive section of Cambridge Examination for Mental Disorders of the Elderly (CAMDEX) The measure assesses orientation, language, memory, praxis, attention, abstract
Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias. Aaron H. Kaufman, MD
Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, MD Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, M.D. Health Sciences
Roche satellite symposium/educational session CTAD Asia - China Conference Transforming AD in China: From Diagnosis to Treatment
Roche satellite symposium/educational session CTAD Asia - China Conference Transforming AD in China: From Diagnosis to Treatment Sunday 2 September 2018 Location: Shanghai, China NP/AZD/1807/0003 Complex
Sponsor Novartis. Generic Drug Name AFQ056. Therapeutic Area of Trial L-dopa induced dyskinesias in Parkinson s disease (PD-LID)
Sponsor Novartis Generic Drug Name AFQ056 Therapeutic Area of Trial L-dopa induced dyskinesias in Parkinson s disease (PD-LID) Approved Indication Investigational Protocol Number CAFQ056A2223 Title 13-week,
Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended)
Issue date: November 2006 (amended September 2007) Review date: September 2009 Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended) Includes a
Management of Behavioral Problems in Dementia
Management of Behavioral Problems in Dementia Ghulam M. Surti, MD Clinical Assistant Professor Department of Psychiatry and Human Behavior Warren Alpert Medical School of Brown University Definition of
The Neuropsychiatric Inventory Questionnaire: Background and Administration
The Neuropsychiatric Inventory Questionnaire: Background and Administration The Neuropsychiatric Inventory Questionnaire (NPI-Q) was developed and crossvalidated with the standard NPI to provide a brief
Dietary Supplements, Caffeine, and Cognitive Aging
Institute of Medicine Committee on the Public Health Dimensions of the National Academies Beckman Center of the National Academies Irvine, CA June 9, 2014 Dietary Supplements, Caffeine, and Cognitive Aging
2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #283: Dementia Associated Behavioral and Psychiatric Symptoms Screening and Management National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY
Behavioural and Psychological Symptoms and Medications Presentation
1 2 Vover s research indicated that antipsychotic med are frequently used for individual presenting with disruptive behaviours. This often combined with physical restraints Efficacy of use not justify
HHS Public Access Author manuscript Am J Geriatr Psychiatry. Author manuscript; available in PMC 2017 January 01.
Trajectories of neuropsychiatric symptoms and cognitive decline in mild cognitive impairment Nicholas D. David, B.A. 1,*, Feng Lin, R.N., Ph.D. 1,2,*, and Anton P. Porsteinsson, M.D. 1, for the Alzheimer
Neuropsychiatric symptoms as predictors of MCI and dementia: Epidemiologic evidence
16th Annual MCI Symposium January 20, 2018 Miami, FL Neuropsychiatric symptoms as predictors of MCI and dementia: Epidemiologic evidence Yonas E. Geda, MD, MSc Professor of Neurology and Psychiatry Consultant,
Supplementary Online Content
Supplementary Online Content Atri A, Frölich L, Ballard C, et al. Effect of idalopirdine as adjunct to cholinesterase inhibitors on in cognition in patients with Alzheimer disease: three randomized clinical
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (Review of TA 111) Appraisal
Behavioral and psychological symptoms of dementia characteristic of mild Alzheimer patients
Blackwell Science, LtdOxford, UKPCNPsychiatry and Clinical Neurosciences1323-13162005 Blackwell Publishing Pty Ltd593274279Original ArticleDementia and mild AlzheimersJ. Shimabukuro et al. Psychiatry and
Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer s Dementia: Evidence From the CitAD Study
ARTICLES Effects of Citalopram on Neuropsychiric Symptoms in Alzheimer s Dementia: Evidence From the CitAD Study Anne K. Leonpacher, M.D., Mthew E. Peters, M.D., Lea T. Drye, Ph.D., Kelly M. Makino, B.S.,
Appendix 5. Characteristics of included studies. Study title: NCT
Appendix 5 Characteristics of included studies Study title: NCT00818662 Study design: 'A Randomized, Double-Blind, Placebo-led, Two Dose Arm, Parallel Study of the Safety and Effectiveness of Immune Globulin
Coordinating Care Between Neurology and Psychiatry to Improve the Diagnosis and Treatment of Parkinson s Disease Psychosis
Coordinating Care Between Neurology and Psychiatry to Improve the Diagnosis and Treatment of Parkinson s Disease Psychosis Jeff Gelblum, MD Senior Attending Neurologist Mt. Sinai Medical Center Miami,
HD 101: Cognition and HD. Daniel O. Claassen, MD MS Assistant Professor of Neurology Director: HD and Chorea Clinic Vanderbilt University
HD 101: Cognition and HD Daniel O. Claassen, MD MS Assistant Professor of Neurology Director: HD and Chorea Clinic Vanderbilt University The information provided by speakers in workshops, forums, sharing/networking
Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch
Molinuevo et al. Alzheimer's Research & Therapy (2015) 7:9 DOI 10.1186/s13195-014-0088-8 RESEARCH Open Access Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine
How Aging and Dementia Effect Resident Behaviors
How Aging and Dementia Effect Resident Behaviors November 3, 2011 1:00 2:00 PM EST Webinar Presented by: Alfred W. Norwood, BS, MBA Education Arm of the Carmelite Sisters for the Aged and Infirm Webinar
DRAFT SLIDES. Michael Huss Child and Adolescent Psychiatry, Johannes Gutenberg University Mainz, Mainz, Germany
DRAFT SLIDES Separating efficacy and sedative effects of guanfacine extended release in children and adolescents with ADHD from four randomized, controlled, phase 3 clinical trials Michael Huss Child and
DLQI (ESTEEM
192 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Moderate to Severe Plaque Psoriasis: Pruritus and DLQI Correlations at Week 16 (ESTEEM 1 and 2) Steven R. Feldman, MD, PhD 1 ; Diamant
Neuropsychiatric Inventory Nursing Home Version (NPI-NH)
This is a Sample version of the Neuropsychiatric Inventory Nursing Home Version (NPI-NH) The full version of the Neuropsychiatric Inventory Nursing Home Version (NPI-NH) comes without sample watermark..
THINC-it: what is it? John Harrison Alzheimer Center, VU University Medical Center, West London Mental Health Trust, Metis Cognition Ltd
THINC-it: what is it? John Harrison Alzheimer Center, VU University Medical Center, West London Mental Health Trust, Metis Cognition Ltd Disclosures Associate Professor in the Alzheimer Center at the VU
LTC Research Influencing Practice
LTC Research Influencing Practice David A. Nace, MD, MPH Division of Geriatric Medicine naceda@upmc.edu PGS Clinical Update April 6, 2017 Conflicts of Interest Dr. Nace does not have any current conflicts
Psychiatric and behavioral symptoms are common in
Article Clinical Symptom Responses to Atypical Antipsychotic Medications in Alzheimer s Disease: Phase 1 Outcomes From the CATIE-AD Effectiveness Trial David L. Sultzer, M.D. Sonia M. Davis, Dr.P.H. Pierre
BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA
BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA Unmet needs What might be your behavioural response to this experience? Content Definition What are BPSD? Prevalence How common are they? Aetiological
Stephen Salloway, M.D., M.S. Disclosure of Interest
Challenges in the Early Diagnosis of Alzheimer s Disease Stephen Salloway, MD, MS Professor of Neurology and Psychiatry Alpert Medical School, Brown University 2 nd Annual Early Alzheimer s Educational
The place for treatments of associated neuropsychiatric and other symptoms
The place for treatments of associated neuropsychiatric and other symptoms Luca Pani dg@aifa.gov.it London, 25 th November 2014 Workshop on Alzheimer s Disease European Medicines Agency London, UK Public
MORTALITY ASSOCIATED WITH USE OF ANTIPSYCHOTICS IN DEMENTIA: REVIEWING THE EVIDENCE
MORTALITY ASSOCIATED WITH USE OF ANTIPSYCHOTICS IN DEMENTIA: REVIEWING THE EVIDENCE KRISTA L. LANCTÔT, PHD PROFESSOR OF PSYCHIATRY AND PHARMACOLOGY, UNIVERSITY OF TORONTO; SENIOR SCIENTIST, HURVITZ BRAIN
AGITATION IN DEMENTIA BEHAVIORAL AND PSYCHIATRIC SYMPTOMS IN DEMENTIA (BPSD) AGITATION SUBGROUP SESSION 20 TH FEBRUARY 2018.
AGITATION IN DEMENTIA BEHAVIORAL AND PSYCHIATRIC SYMPTOMS IN DEMENTIA (BPSD) AGITATION SUBGROUP SESSION 20 TH FEBRUARY 2018. BRIEF OVERVIEW: AGITATION ASSOCIATED WITH ALZHEIMER S DISEASE (AD) AD afflicts
Worldwide, over 40 million people have. Pimavanserin in Alzheimer s Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms
The Journal of Prevention of Alzheimer s Disease - JPAD Volume 6, Number 1, 2019 Original Research The Author(s) Pimavanserin in Alzheimer s Disease Psychosis: Efficacy in Patients with More Pronounced
Behavioral Interventions
Behavioral Interventions Linda K. Shumaker, R.N.-BC, MA Pennsylvania Behavioral Health and Aging Coalition Behavioral Management is the key in taking care of anyone with a Dementia! Mental Health Issues
SYNOPSIS (FOR NATIONAL AUTHORITY USE ONLY) INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER
SYNOPSIS Protocol No.: RIS-USA-63 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: A randomized, double-blind, placebo controlled study of risperidone for treatment of behavioral disturbances
XP23829 PHASE 2 PSORIASIS TRIAL PRELIMINARY TOPLINE DATA PRESENTATION SEPTEMBER 15, 2015 COPYRIGHT 2015 XENOPORT, INC. ALL RIGHTS RESERVED.
XP23829 PHASE 2 PSORIASIS TRIAL PRELIMINARY TOPLINE DATA PRESENTATION SEPTEMBER 15, 2015 COPYRIGHT 2015 XENOPORT, INC. ALL RIGHTS RESERVED. SAFE HARBOR DISCLAIMER These slides and the accompanying oral
Anne M. Calkins, 1 Joseph Shurman, 2 Mark Jaros, 3 Richard Kim, 4 Gwendoline Shang 4. New York Spine and Wellness Center, North Syracuse, NY; 2
Peripheral Edema and Weight Gain in Adult Patients With Painful Diabetic Peripheral Neuropathy Receiving Gabapentin Enacarbil or Pregabalin Enrolled in a Randomized, Phase 2 Trial Anne M. Calkins, 1 Joseph
Known as both a thief and murderer,
&A Dementia Drugs: When Should They Be Stopped? Ron Keren, MD, FRCPC As presented at the University of Toronto s Primary Care Conference, Toronto, Ontario (May 25) Known as both a thief and murderer, Alzheimer
Industry Relationships and Institutional Affiliations
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated daily statin: results from the ODYSSEY COMBO II study Christopher
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Nuedexta) Reference Number: CP.PMN.93 Effective Date: 12.05.17 Last Review Date: 02.19 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
Dementia of the Alzheimer Type: the Drug Treatment Debate
Dementia of the Alzheimer Type: the Drug Treatment Debate I have no financial conflict of interest. Many years ago I was given a trip to San Fran and taught to use a slide set from the drug company. I
Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis (UNVEIL Phase IV Study)
4892 Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis ( Phase IV Study) Bruce Strober, MD 1 ; Jerry Bagel, MD 2 ; Mark Lebwohl, MD 3 ; Linda Stein Gold, MD 4 ; J. Mark Jackson,
Cummings et al. Alzheimer's Research & Therapy (2018) 10:116 (Continued on next page)
Cummings et al. Alzheimer's Research & Therapy (2018) 10:116 https://doi.org/10.1186/s13195-018-0443-2 RESEARCH Open Access Insights into globalization: comparison of patient characteristics and disease
Long-Term Care Updates
Long-Term Care Updates March 2017 By Darren Hein, PharmD Nuedexta is a fixed combination of dextromethorphan, an uncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist,
Abstract Background: Methods: Results: Conclusion:
1131 Efficacy of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Palmoplantar Psoriasis in Patients With Moderate to Severe Plaque Psoriasis in Phase 2 and Phase 3 (ESTEEM) Trials Robert Bissonnette,
Deficits in Emotional Regulation in ADHD
Deficits in Emotional Regulation in ADHD Joseph Biederman, MD Professor of Psychiatry Harvard Medical School Chief, Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD Massachusetts
Month/Year of Review: September 2013 Date of Last Review: February 2012
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights
Pharmacological Treatments for Tobacco Users with Behavioral Health Conditions
Pharmacological Treatments for Tobacco Users with Behavioral Health Conditions Jill M Williams, MD Professor Psychiatry Director, Division Addiction Psychiatry Robert Wood Johnson Medical School Disclosures
Treatment development for neuropsychiatric symptoms in Alzheimer dementia Where are we headed?
Treatment development for neuropsychiatric symptoms in Alzheimer dementia Where are we headed? Constantine G. Lyketsos, MD, MHS Chair of Psychiatry, Johns Hopkins Bayview Elizabeth Plank Althouse Professor,
Neurocognitive Disorders Research to Emerging Therapies
Neurocognitive Disorders Research to Emerging Therapies Edward Huey, MD Assistant Professor of Psychiatry and Neurology The Taub Institute for Research on Alzheimer s Disease and the Aging Brain Columbia
WHY FOCUS ON APATHY? DIAGNOSIS, SYMPTOMS ASSESSMENT, METHODOLOGY FRAMEWORK. David S. Miller, MD, MA 2 September 2017 ISCTM
WHY FOCUS ON APATHY? DIAGNOSIS, SYMPTOMS ASSESSMENT, METHODOLOGY FRAMEWORK David S. Miller, MD, MA 2 September 2017 ISCTM ALTERNATE TITLE: WHO'LL STOP THE TRAIN? David S. Miller, MD, MA 2 September 2017
Prediction of Relapse After Discontinuation of Antipsychotic Treatment in Alzheimer s Disease: The Role of Hallucinations
ARTICLES Prediction of Relapse After Discontinuation of Antipsychotic Treatment in Alzheimer s Disease: The Role of Hallucinations Anjali N. Patel, D.O., Seonjoo Lee, Ph.D., Howard F. Andrews, Ph.D., Gregory
Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia A Randomized Clinical Trial
Research Original Investigation Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia A Randomized Clinical Trial Jeffrey L. Cummings, MD, ScD; Constantine G. Lyketsos,
Summary ID#7029. Clinical Study Summary: Study F1D-MC-HGKQ
CT Registry ID# 7029 Page 1 Summary ID#7029 Clinical Study Summary: Study F1D-MC-HGKQ Clinical Study Report: Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated with Bipolar
Supplementary Online Content
Supplementary Online Content Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized controlled trial. JAMA. doi:10.1001/jama.2014.93 eappendix.
DEPRESSIVE SYMPTOMS IN ADULT CHILD CAREGIVERS OF VERY OLD MEXICAN AMERICANS: A STUDY OF THE HEPESE
DEPRESSIVE SYMPTOMS IN ADULT CHILD CAREGIVERS OF VERY OLD MEXICAN AMERICANS: A STUDY OF THE HEPESE David V. Flores, PhD, LMSW, MPH University of Texas Medical Branch Galveston UNIVERSITY OF SOUTHERN CALIFORNIA
Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition
Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition Article (Published Version) Cummings, J, Mintzer, J, Brodaty, H, Sano,
Antipsychotic Medications
TRAIL: Team Review of EVIDENCE REVIEW & RECOMMENDATIONS FOR LTC Behavioural and psychological symptoms of dementia (BPSD) refer to the non-cognitive symptoms of disturbed perception, thought content, mood
Assessment and management of behavioral and psychological symptoms of dementia
Assessment and management of behavioral and psychological symptoms of dementia Helen C Kales, 1 2 3 Laura N Gitlin, 4 5 6 Constantine G Lyketsos 7 1 Section of Geriatric Psychiatry, Department of Psychiatry,
Previous Study Return to List Next Study
A service of the U.S. National Institutes of Health Trial record 1 of 1 for: 42603ATT3013 Previous Study Return to List Next Study A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS
Although cholinesterase inhibitors (ChEIs) and memantine
High-dose donepezil or memantine: Next step for Alzheimer s disease? Larger dosages may benefit patients who have maxed out existing therapies Indrapal Singh, MD Assistant Professor Department of Geriatric
Mental Health Issues in Nursing Homes. I m glad you asked.
Mental Health Issues in Nursing Homes I m glad you asked. I m glad you asked Susan Wehry, M.D. Associate Professor of Psychiatry, College of Medicine, University of Vermont Consultant, State of Vermont
NIH Public Access Author Manuscript Dement Geriatr Cogn Disord. Author manuscript; available in PMC 2013 August 28.
NIH Public Access Author Manuscript Published in final edited form as: Dement Geriatr Cogn Disord. 2012 ; 34(2): 96 111. doi:10.1159/000342119. Neuropsychiatric symptoms and global functional impairment
This was a randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
Clinical Trial Results Database Page 1
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major Depressive Disorder (MDD) Approved Indication Treatment of major depressive
University of California, San Diego, School of Medicine, La Jolla, CA, USA; 2
2194 Long-term (104-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis: Results From a Phase III, Randomized, Controlled Trial
CHCS. Multimorbidity Pattern Analyses and Clinical Opportunities: Dementia. Center for Health Care Strategies, Inc. FACES OF MEDICAID DATA SERIES
CHCS Center for Health Care Strategies, Inc. FACES OF MEDICAID DATA SERIES Multimorbidity Pattern Analyses and Clinical Opportunities: Dementia December 2010 Cynthia Boyd, MD, MPH* Bruce Leff, MD* Carlos
ANTIPSYCHOTICS IN LONG TERM CARE: Are We Doing More Harm than Good?
ANTIPSYCHOTICS IN LONG TERM CARE: Are We Doing More Harm than Good? STEPHANIE M. OZALAS, PHARMD, BCPS, BCGP VA MARYLAND HEALTH CARE SYSTEM BALTIMORE, MD DISCLOSURES Off-label use of medications will be
CitAD Protocol Version 2.3
Citalopram for Agitation in Alzheimer s Disease (CitAD) CitAD Protocol Version 2.3 Repository: CitAD Coordinating Center Johns Hopkins University 911 South Ann Street Baltimore, Maryland 21231 (443) 287-3170
EFFECT OF PRIDOPIDINE ON MOTOR FUNCTION IN PATIENTS WITH HUNTINGTON DISEASE: RESULTS FROM THE HART STUDY
EFFECT OF PRIDOPIDINE ON MOTOR FUNCTION IN PATIENTS WITH HUNTINGTON DISEASE: RESULTS FROM THE HART STUDY HSG HART Investigators Presented by Karl Kieburtz, MD, MPH Director, Center for Human Experimental
Worldwide, over 40 million people have. Pimavanserin in Alzheimer s Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms
The Journal of Prevention of Alzheimer s Disease - JPAD Volume 6, Number 1, 2019 Original Research The Author(s) Pimavanserin in Alzheimer s Disease Psychosis: Efficacy in Patients with More Pronounced
Recommendations For the Use of Donepezil
Recommendations For the Use of Donepezil The trial of donepezil in patients with mild to moderate dementia due to probable AD was one recommendation made by the Canadian Consensus Conference on Dementia.
Alzheimer s Disease Update: From Treatment to Prevention
Alzheimer s Disease Update: From Treatment to Prevention Jeffrey M. Burns, MD Edward H. Hashinger Professor of Medicine Co-Director, KU Alzheimer s Disease Center Director, Clinical and Translational Science
MANAGEMENT OF NEUROPSYCHIATRIC SYMPTOMS OF DEMENTIA
MANAGEMENT OF NEUROPSYCHIATRIC SYMPTOMS OF DEMENTIA Dr. Dallas Seitz MD PhD FRCPC Associate Professor and Division Chair, Division of Geriatric Psychiatry Department of Psychiatry, Queen s University President,
City, University of London Institutional Repository
City Research Online City, University of London Institutional Repository Citation: Hurt, C. S., Banerjee, S., Tunnard, C., Whitehead, D. L., Tsolaki, M., Mecocci, P., Kloszewska, I., Soininen, H., Vellas,
Evidence-Based Interventions to Improve Caregiver and Patient Outcomes in Dementia
Evidence-Based Interventions to Improve Caregiver and Patient Outcomes in Dementia Alan B. Stevens, PhD Professor, Department of Medicine Vernon D. Holleman-Lewis M. Rampy Centennial Chair in Gerontology
Disclosures. REPLENISH Trial: Objective and Design. Background Use of compounded bioidentical hormone therapy (CBHT) has become highly prevalent
17β Estradiol/Progesterone in a Single Oral Softgel Capsule (TX 001HR) Significantly Reduced Moderate to Severe Vasomotor Symptoms without Endometrial Hyperplasia Disclosures Research support: Actavis,
First Real-World Insights on Apremilast Therapy for Patients With Plaque Psoriasis From the LAPIS-PSO Study: An Interim Analysis
5137 First Real-World Insights on Apremilast Therapy for Patients With Plaque Psoriasis From the Study: An Interim Analysis Kristian Reich, MD 1 ; Stefanie Bomas, MD 2 ; Bernhard Korge, MD 3 ; Maria Manasterski,